Spots Global Cancer Trial Database for Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Lenalidomide and Dexamethasone for Treatment of Patients With Acute Myeloma (Light Chain)-Induced Renal Failure
Official Title:
Study ID: NCT00902915
Interventions
Study Description
Brief Summary: The purpose of this study is to determine efficacy of lenalidomide and dexamethasone in the treatment of patients with acute Myeloma (light chain)-induced renal failure.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
LKH Salzburg, 3rd Med. Dept., Salzburg, , Austria
Austrian Forum Against Cancer; 1st Med. Dept., Center for Hematology and Oncology, Wilhelminenspital, Montleartstrasse 37, Vienna, , Austria
Clinic Wels-Grieskirchen, 4th Internal Dept., Wels, , Austria
Faculty Hospital Brno and Faculty of Medicine MU, Brno, , Czech Republic
Charles University Prague, Prague, , Czech Republic
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
